AstraZeneca drug does not extend lives of breast cancer patients – Financial Times

by
  1. AstraZeneca drug does not extend lives of breast cancer patientsFinancial Times
  2. AstraZeneca, competitor to Daiichi’s Trodelvy, fails to improve overall survival in breast cancer trialFierce biotechnology
  3. Datopotamab Deruxtecan Overall Survival Results Reported in Patients with Metastatic HR-Positive, HER2-Low or -Negative Breast Cancer in TROPION-Breast01 Phase 3 StudyBusiness news
  4. AstraZeneca, Daiichi suffer new setback with mixed results from breast cancer drugsBloomberg
  5. AstraZeneca makes surprise blunder on cancer drug that competes with GileadInvestors Business Daily

Leave a Comment